Trade
Alkem Laboratories share price
Balanced risk
You have to be logged in to add this to Watchlist.- ₹5,688.65(1.61%)July 15, 2026 10:32:15 AM IST
- NSE
- BSE
- Vol : 15.59 K (NSE + BSE)Last 20 day avg : 233.01 K
Alkem Laboratories is trading 1.61% upper at Rs 5,688.65 as compared to its last closing price. Alkem Laboratories has been trading in the price range of 5,701.50 & 5,578.05. Alkem Laboratories has given 1.73% in this year & -1.16% in the last 5 days. Alkem Laboratories has TTM P/E ratio 27.53 as compared to the sector P/E of 25.20.There are 18 analysts who have initiated coverage on Alkem Laboratories. There are 4 analysts who have given it a strong buy rating & 5 analysts have given it a buy rating. 2 analysts have given the stock a sell rating.The company posted a net profit of 236.46 Crores in its last quarter.Listed peers of Alkem Laboratories include Divi's Laboratories (1.88%), Cipla (0.14%), Sun Pharmaceutical Industries (0.97%).The Mutual Fund holding in Alkem Laboratories was at 16.71% in 30 Jun 2026. The MF holding has increased from the last quarter. The FII holding in Alkem Laboratories was at 10.42% in 30 Jun 2026. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Key Metrics
Updated on Jul 15, 2026, 05:04 AM UTC
- BetaLow volatility0.79Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.15The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldInline with the industry0.95Annual dividends as a percentage of the stock price.
- P/BIn line with historical values4.82The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values28.92Price-to-earnings ratio based on trailing 12-month earnings
- PEG RatioIndicates undervaluation0.88The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Alkem Laboratories News
Alkem Laboratories Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Divi's Laboratories | 7,320.00 | 1.88 | 1,94,323.00 | 78.61 | 11.52 | 0.46 | 0.01 |
| Cipla | 1,440.50 | 0.14 | 1,16,370.12 | 22.95 | 3.87 | 0.87 | 0.81 |
| Sun Pharmaceutical Industries | 1,958.90 | 0.97 | 4,69,994.66 | 36.24 | 5.77 | 0.92 | 0.50 |
| Torrent Pharmaceuticals | 4,946.35 | -0.50 | 1,67,459.18 | 67.32 | 17.1 | 0.83 | 17.62 |
| Dr Reddy's Laboratories | 1,233.90 | -0.95 | 1,02,985.83 | 18.63 | 3.14 | 0.63 | 2.34 |
Mutual Fund Ownership
View allAlkem Laboratories Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-05-28 | Audited Results & Final Dividend |
| 2026-02-13 | Quarterly Results & Interim Dividend |
| 2025-11-13 | Quarterly Results |
| 2025-08-12 | Quarterly Results |
| 2025-05-29 | Audited Results & Final Dividend |
About the company Alkem Laboratories
- IndustryBiotechnology & Drugs
- ISININE540L01014
- BSE Code539523
- NSE CodeALKEM
Alkem Laboratories Ltd. is an India-based pharmaceutical company engaged in the development, manufacturing, and sale of pharmaceutical products. The Company operates in a single business segment-Pharmaceuticals. It produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, which it markets in India and international markets. It has a portfolio of approximately 800 brands in India and maintains a presence in over 40 international markets, with the United States being its key focus market. Its offerings include therapies, prescription (Rx) products, and Alkem generics. Its therapy offerings cover multiple medical fields, including anti-infectives, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory care, rheumatology, and urology. The Company’s subsidiaries include Ascend Laboratories (Pty) Ltd, Pharmacor Pty Limited, Alkem Laboratories Corporation, and others.
Alkem Laboratories Share Price FAQs
Alkem Laboratories is trading at 5688.65 as on Wed Jul 15 2026 05:02:15. This is 1.61% upper as compared to its previous closing price of 5598.35.
The market capitalization of Alkem Laboratories is 67923.53 Cr as on Wed Jul 15 2026 05:02:15.
The average broker rating on Alkem Laboratories is Buy. The breakup of analyst rating is given below -
- 4 analysts have given a strong buy rating
- 5 analysts have given a buy rating
- 6 analysts have given a hold rating
- 2 analysts have given a sell rating
- 1 analysts have given a strong sell rating
The 52 wk high for Alkem Laboratories is 5933.00 whereas the 52 wk low is 4740.65
Alkem Laboratories can be analyzed on the following key metrics -
- TTM P/E: 27.53
- Sector P/E: 25.20
- Dividend Yield: 0.95%
- D/E ratio: 0.15
Alkem Laboratories reported a net profit of 2301.80 Cr in 2026.
The Mutual Fund Shareholding was 16.71% at the end of 30 Jun 2026.
Quick Links
EQUITY QUICK LINKS
Alkem Laboratories QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.